Kidswell Bio Corporation [4584.T]
TOKYO, May 14 (Pulse News Wire) – Kidswell Bio Corporation (4584.T) reported higher revenue of ¥6,589,923 thousand for its fiscal year ending March 2026 compared to the previous year. However, the company incurred a lower net profit of ¥413,994 thousand due to increased research and development expenses and operational costs.
Revenue grew significantly, driven by an increase in product deliveries and price adjustments for certain supplies. Despite these challenges, the standalone biologic similar division maintained profitability. In the coming fiscal year, Kidswell expects to achieve operating profitability despite potential impacts from newly launched products.
The company plans to continue focusing on cost reduction strategies and improving supply chain efficiency. Additionally, Kidswell anticipates reaching its goal of achieving operating profit in fiscal 2026. Looking ahead, Kidswell will closely monitor manufacturing schedules and collaborate with pharmaceutical partners to refine future earnings forecasts.
The company also continues to advance its pipeline through partnerships and clinical trials, aiming to enhance shareholder value.
🟡 Confidence: Standard AI-translated content.